ASP5502
/ Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 26, 2026
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
(clinicaltrials.gov)
- P1 | N=116 | Terminated | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Jul 2027 ➔ Mar 2026 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2027 ➔ Mar 2026; Company's strategic decision
Biomarker • Trial completion date • Trial primary completion date • Trial termination • Immunology • Sjogren's Syndrome
August 29, 2024
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
(clinicaltrials.gov)
- P1 | N=132 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Sjogren's Syndrome
August 09, 2024
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
(clinicaltrials.gov)
- P1 | N=132 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.
Biomarker • New P1 trial • Immunology • Sjogren's Syndrome
1 to 3
Of
3
Go to page
1